Bristol Myers Squibb (BMY)
(Delayed Data from NYSE)
$41.24 USD
-0.30 (-0.72%)
Updated May 24, 2024 04:00 PM ET
After-Market: $41.26 +0.02 (0.05%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth D Momentum B VGM
Price, Consensus and EPS Surprise
BMY 41.24 -0.30(-0.72%)
Will BMY be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for BMY based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for BMY
Why Cytokinetics (CYTK) Stock Price Was Down 17% on Thursday
Bristol Myers (BMY) Updates Action Date for Subcutaneous Opdivo
BMY: What are Zacks experts saying now?
Zacks Private Portfolio Services
The Zacks Analyst Blog Highlights Novavax, Sanofi, Fulcrum Therapeutics, Moderna and Bristol Myers
Walmart Earnings & the State of the Consumer
Biotech Stock Roundup: NVAX, FULC Up on Deals With SNY, Updates From MRNA, BMY
Other News for BMY
10 Health Care Stocks With Whale Alerts In Today's Session
Retail Earnings & Consumer Spending: A Closer Look
Sell Alert: 2 Dividend Stocks To Sell In May And Go Away
Catalyst Watch: Costco earnings, M&A drama, Viking ratings, and a key inflation read
Bristol Myers Squibb to Present Data at ASCO & EHA from More Than 130 Studies Across 25 Diseases Supporting Expansion into New Indications, Demonstrating Long-Term Survival, and Highlighting Novel Modalities and Research Platforms